Stocks · News reference

Why Are 42% of US Cancer Patients Draining Their Life Savings in Two Years? Bernie Sanders Has a $400,000 Answer

Sep 2, 2026, 10:56 AMNamrata Sen

Bernie Sanders blasts Big Pharma over $400,000 cancer drugs, warning soaring treatment costs can push patients into financial ruin.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaOct 5, 2026, 12:02 PMBenzinga Newsdesk
Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that
RVMD
BenzingaSep 28, 2026, 4:55 PMBenzinga Newsdesk
Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318
Brookline Capital analyst Leah Rush initiates coverage on Revolution Medicines (NASDAQ:RVMD) with a Buy rating and announces Price Target of $318.
RVMD
BenzingaSep 24, 2026, 12:21 PMBenzinga Newsdesk
Goldman Sachs Reinstates Buy on Revolution Medicines, Announces $267 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Revolution Medicines (NASDAQ:RVMD) with a Buy and announces $267 price target.
RVMD
BenzingaSep 21, 2026, 5:38 PMBenzinga Newsdesk
B of A Securities Maintains Buy on Revolution Medicines, Raises Price Target to $265
B of A Securities analyst Alec Stranahan maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $225 to $265.
RVMD